Dr Reddy’s launches antibiotic drug in US

Tags: News
Indian drug maker Dr Reddy’s has launched a generic and low priced version of the brand Avelox which is under marketing license with Merck. For the US market, the brand has total sales of $195 million at the end of one year in December 2013, estimates IMS Health.

The tablets which have Moxifloxacin Hydrochloride as active ingredient would come in 400 mg form. “Presenty, the competition for the drug is low, with only two other generic players, that is Teva and Aurobindo Pharma with approvals. We expect Dr Reddy’s to post sales of $20 million and net profit $5 million for this drug,” said Sarabjit Kour Nangra, senior vice-president (research, pharma) — Angel Broking.

The anti-infective (bacterial infections) drug contains moxifloxacin which is associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is aggravated in patients above 60 years of age and taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. While Bayer Healthcare manufactures the branded drug, Merck distributes it.

trushnaudgirkar

@mydigitalfc.com

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Bureaucrats have enjoyed flying miles at taxpayer expense for too long

    The beleaguered Indian taxpayer will certainly applaud prime minister Narendra Modi’s attempt to deliver on his promise of cutting down fiscal defic

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Varun Dutt

<b>Riskfactor</b>: CHAIN REACTION

A domino effect is the cumulative effect produced when one ...

Zehra Naqvi

Rememberance and forgetting are crucial

Memories are so vital to our lives that they can ...

Dharmendra Khandal

Sandalwood may get extinct if not protected

When we talk of sandalwood, the most common usage that ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture